Samsung Bioepis And Organon Line Up Interchangeable Adalimumab

Firms Prepare To File For Interchangeability With FDA For Hadlima Rival To Humira

 
• By Dave Wallace

Samsung Bioepis and Organon have announced results from an interchangeability study for their Hadlima biosimilar rival to Humira, also disclosing plans to file for a US interchangeability designation.

Interchangeable Swap Icon
Samsung Bioepis and Organon are pursuing interchangeability for Hadlima • Source: ValentinT / Alamy Stock Photo

Samsung Bioepis and Organon have revealed that they are on the verge of filing with the US Food and Drug Administration for an interchangeability designation for their Hadlima (adalimumab-bwwd) biosimilar rival to Humira, after publishing positive trial data.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products